On Friday, Dollar Tree, Inc. (NASDAQ:DLTR)’s shares inclined 1.49% to $81.66.
Dollar Tree, Inc. (DLTR) an operator of discount variety stores offering merchandise at a fixed price point of $1.00, seems to have a compelling growth story given its progress on the back of endeavors, including store expansion, omni-channel development and penetration into new markets.
However, the stock was let down by its performance in first-quarter fiscal 2015, wherein both top and bottom lines missed the Zacks Consensus Estimate, as sales were hurt by an unfavorable shift in Easter holiday timing and labor disruptions at the West Coast port. Also, the company had to pay incremental freight costs on account of alternate ports.
These headwinds triggered management to tweak its outlook for the fiscal, following which the stock witnessed downward estimate revisions.
Dollar Tree now anticipates sales for the fiscal to be in the range of $9.24–$9.42 billion, contrast with $9.21–$9.45 billion predicted earlier, based on the expectation that comps will grow in a low to low-mid single-digit range in fiscal 2015. Moreover, the company now envisions adjusted earnings per share for fiscal 2015 to be in the band of $3.32–$3.47 contrast with $3.30–$3.50 projected earlier.
Dollar Tree, Inc. operates discount variety stores in the United States and Canada. Its stores offer merchandise at the fixed price of $1.00. The company’s stores provide consumable merchandise, which comprises candy and food, and health and beauty care products; and everyday consumables, such as paper and chemicals, and frozen and refrigerated food. Its stores also offer various merchandise that comprise toys, durable housewares, gifts, party goods, greeting cards, softlines, and other items; and seasonal goods comprising of Valentine’s Day, Easter, Halloween, and Christmas merchandise.
Peregrine Pharmaceuticals (NASDAQ:PPHM)’s shares gained dropped -1.47% to $1.34.
Peregrine Pharmaceuticals (PPHM) a biopharmaceutical company focused on developing novel investigational products that assist harness the body’s own immune system to fight cancer, declared that the European Patent Office (EPO) has granted Patent Number 2,269,656, titled “Selected Antibodies Binding to Aminophospholipids and their Use in Treatment, Such as Cancer”. This important patent covers bavituximab as a composition of matter and for use in treating cancer counting in combination with radiotherapy or chemotherapy, such as with docetaxel.
The new patent covers bavituximab as a composition of matter, a range of related antibodies, counting humanized and chain-shuffled antibodies and other sequence variations and their broad use in any diagnosis or therapy. The new patent also covers antibody drug conjugates, diagnostic and imaging constructs, liposomal and pharmaceutical combinations of bavituximab and related antibodies.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer together with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.
At the end of Friday’s trade, PhotoMedex Inc (NASDAQ:PHMD)‘s shares dipped -6.71% to $1.53.
PhotoMedex Inc (PHMD) declares the sale of its worldwide XTRAC® and VTRAC® psoriasis and vitiligo treatment businesses to MELA Sciences, Inc. (MELA) for $42.5 million in cash. In addition, the company declares it has paid off in full all outstanding debt, which totaled $40.1 million as of June 22, 2015.
PhotoMedex is now able to focus solely on our core consumer and skincare businesses, counting the no!no!™, Kyrobak® and Neova® brands, without the burden of debt payments and the restrictions of forbearance agreements. These highly-regarded and established brands are sold worldwide via direct-to-consumer, retail and distribution channels, and through more than 2,400 U.S. dermatology and plastic surgery offices,” said Dr. Dolev Rafaeli, chief executive officer of PhotoMedex.
PhotoMedex, Inc., a skin health company, provides integrated disease administration and aesthetic solutions to dermatologists, professional aestheticians, and consumers in North America, the Asia Pacific, Europe, and South America. The company operates in three segments: Consumer, Physician Recurring, and Professional. It offers products and services that address skin diseases and conditions, counting psoriasis, vitiligo, acne, and photo damage. The company also provides a range of home-use devices under the no!no! brand name for various indications, such as hair removal, acne treatment, skin rejuvenation, and lower back pain; and a professional product line for acne clearance, skin tightening, psoriasis care, and hair removal to physician clinics and spas.
Web.com Group Inc (NASDAQ:WWWW), ended its Friday’s trading session with 1.26% gain, and closed at $24.11.
Web.com Group Inc (WWWW) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $22.27 to $23.27 in the past one-month time frame.
The company has seen no estimate revision over the past 30 days, while the Zacks Consensus Estimate remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Web.com Group, Inc. provides Internet services to small businesses in North America, South America, and the United Kingdom. The company offers a range of Web services and products that enable small businesses to establish, maintain, promote, and optimize their online presence. It provides domain name registration, such as .com and .net domains, in addition to a suite of domain name services, counting domain name registration, transfers, renewals, expiration protection, and privacy services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
